Calidi Biotherapeutics, a clinical-stage biotechnology company specializing in allogeneic cell-based delivery of oncolytic viruses, has announced a commitment of $25 million in Series B funding. The funding round is led by Jackson Investment Group (JIG), with an initial investment of $5 million, and participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi. The remaining commitment is contingent upon the completion of the previously announced business combination between First Light Acquisition Group and Calidi.
The financing will enable Calidi to advance its pipeline, which includes the development of CLD-101, CLD-201, and CLD-202. These programs utilize a combination of potent allogeneic stem cells and oncolytic viruses for the treatment of various oncology indications.
Calidi’s unique approach of using stem cells to deliver and potentiate oncolytic viruses in the fight against cancer has garnered support from investors. Rick Jackson, CEO of Jackson Investment Group, expressed confidence in Calidi’s technology and its potential to make a significant impact in addressing the unmet needs of patients with cancer.
The transaction was facilitated by Brookline Capital Markets, acting as the placement agent for the Series B funding round.
